International Drug Sourcing: 5 Questions Every Benefits Buyer Should Ask
International drug sourcing has become an attractive option for employers looking to manage rising prescription drug costs. With certain medications available at lower prices outside of the United States, the potential for savings can be significant, particularly for plans managing a high volume of high-cost prescriptions.
What many forget to consider, however, is that a lower purchase price does not always translate into a lower total cost or a sustainable pharmacy benefit strategy.
International sourcing introduces considerations that extend beyond pricing, including regulatory requirements, medication availability, shipping logistics, and the potential for interruptions in member access.
Recent developments have brought those considerations into sharper focus. In June 2026, the FDA authorized Colorado to import certain prescription medications from Canada, making it the second state to receive approval.
However, implementing these programs remains challenging. Florida, which received authorization in 2024, had not begun importing medications as of June 2026.
At the same time, recent changes to U.S. customs requirements could create additional administrative and financial hurdles for certain international shipments.
For brokers, third-party administrators (TPAs), and self-funded employers, these developments raise an important question: How dependable are the savings associated with international drug sourcing?
Before incorporating international sourcing into a pharmacy benefit strategy, benefits coordinators and consultants should consider these five questions.
1. How much of the projected savings depends on international sourcing?
Cost savings are the primary reason employers explore international drug sourcing. Certain medications may be available at substantially lower prices through international channels, creating opportunities to reduce spending on high-cost prescriptions.
However, the projected savings may depend on assumptions that are not explicitly stated in a proposal.
For example, a pharmacy benefit solution may project annual savings based on the expectation that specific medications will remain available internationally at favorable prices. If availability changes or additional costs arise, the actual financial benefit could look very different.
Brokers and employers should ask vendors to distinguish between savings generated through international sourcing and those achieved through other cost-management strategies.
A few considerations can help inform that evaluation:
What percentage of projected savings depends on internationally sourced medications?
Are shipping, customs, administrative fees, and other expenses included in the savings calculations?
How would projected savings change if international sourcing became unavailable?
Understanding these dependencies helps employers evaluate whether the proposed savings are sustainable and how much financial exposure the plan could face if sourcing conditions change.
2. Which medications can actually be sourced internationally, and which cannot?
The FDA regulates the importation of prescription drugs into the United States, but different requirements apply depending on the type of medication and the sourcing pathway.
Under the FDA's Section 804 Importation Program, for example, authorized state programs can import certain prescription drugs from Canada under specified safety and regulatory conditions. That authorization does not extend to every medication or every type of international sourcing arrangement.
Some medications may be excluded from direct importation programs, while others may be difficult to source because of manufacturer restrictions, limited supply, or specific handling requirements.
This is particularly relevant for specialty medications, where the drugs responsible for significant plan spending may also have more complex distribution or clinical requirements.
Rather than assuming international sourcing can address an entire category of high-cost medications, employers should evaluate the specific drugs included in a proposed program. The medication list should reflect actual plan utilization, with clearly identified sourcing options, applicable restrictions, and realistic savings estimates.
3. What happens if a medication becomes unavailable or the sourcing pathway changes?
A medication available at a favorable price today may become difficult to obtain because of supply limitations, manufacturer decisions, regulatory changes, or shifts in international distribution.
As STAT reported in June 2026, Florida's authorized Canadian drug importation program had yet to begin importing medications more than two years after receiving FDA approval. Concerns about Canadian drug supply and resistance from parts of the pharmaceutical industry were among the obstacles.
For plan sponsors, this illustrates the difference between identifying a lower-cost sourcing opportunity and maintaining dependable access to that opportunity.
A sourcing strategy should account for what happens when the preferred channel is no longer available. Without a documented contingency plan, an unexpected supply change could create additional administrative work, higher costs, or delays in prescription fulfillment.
4. What regulatory, customs, or supply-chain factors could disrupt access or increase costs?
International sourcing arrangements operate within a regulatory environment that can change quickly, sometimes with significant financial and operational consequences.
A recent example is the U.S. Customs and Border Protection rule affecting certain international mail shipments.
The rule includes new entry procedures and compliance requirements, with additional provisions scheduled to take effect on October 22, 2026.
According to September 2026 reporting from STAT, lawmakers raised concerns that the requirements, including customs broker involvement and entry bonds, could make it more difficult and expensive for Americans to obtain medications through certain international pharmacy channels.
The implications depend on the specific sourcing arrangement. Requirements affecting personally imported medications are not necessarily the same as those governing authorized commercial or state importation programs.
For employers evaluating a program, the review should extend beyond whether medications can be purchased internationally today.
It should also address who monitors regulatory developments, who manages customs compliance, and whether additional costs could be passed along to the plan or its members.
5. What is the impact on the member if international sourcing is delayed or no longer available?
For employers, prescription drug costs are a financial concern. For members, access to their medications is often a more immediate priority.
A member managing a chronic condition may rely on a consistent medication supply. If an international shipment is delayed or a sourcing arrangement becomes unavailable, the member needs to know how their prescription will be filled.
Employers and brokers should understand how the vendor handles prescription delays, communicates with members, and coordinates alternative prescription fulfillment when necessary.
A lower-cost sourcing arrangement may create financial value for the plan, but that value must be evaluated alongside the service and support required to maintain access.
This is especially important for members using specialty medications, where delays or changes in treatment may require coordination with prescribing providers.
Employers and brokers should expect vendors to explain their member support process before a disruption occurs, including how members are notified and how alternative fulfillment is coordinated.
Evaluating International Drug Sourcing as Part of a Broader Pharmacy Strategy
International sourcing can offer meaningful cost-saving opportunities for certain medications. However, the savings available through those arrangements depend on factors that can change throughout the plan year.
For brokers, TPAs, and self-funded employers, evaluating those dependencies is an essential part of determining whether a program is appropriate for the plan.
The strongest evaluations look at the total cost of the medication, the reliability of the sourcing pathway, and the operational support available when circumstances change.
Rescription approaches pharmacy cost management with an emphasis on understanding the actual cost of medications and identifying opportunities to reduce unnecessary spending.
A more informed pharmacy strategy starts with asking the right questions, understanding the risks behind projected savings, and ensuring cost-management decisions account for the people who depend on their prescriptions.
Interested in taking a closer look at your pharmacy benefit strategy? Contact Rescription to learn how a more targeted approach to high-cost medications can help your organization evaluate savings opportunities while keeping member needs in focus.
Sources:
Stakeholders urge Labor Department to finalize PBM transparency rule, Healthcare Dive
